Pyelonephritis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Pyelonephritis – Pipeline Review, H1 2018’, provides an overview of the Pyelonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Pyelonephritis

– The report reviews pipeline therapeutics for Pyelonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pyelonephritis therapeutics and enlists all their major and minor projects

– The report assesses Pyelonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pyelonephritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pyelonephritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

AstraZeneca Plc

Entasis Therapeutics Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Paratek Pharmaceuticals Inc

Zavante Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pyelonephritis Overview

Pyelonephritis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pyelonephritis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pyelonephritis Companies Involved in Therapeutics Development

Achaogen Inc

AstraZeneca Plc

Entasis Therapeutics Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Paratek Pharmaceuticals Inc

Zavante Therapeutics Inc

Pyelonephritis Drug Profiles

(AAI-101 + cefepime) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam + ceftazidime) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem + vaborbactam) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-2514 + sulbactam sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nacubactam Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulopenem Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pyelonephritis Dormant Projects

Pyelonephritis Discontinued Products

Pyelonephritis Product Development Milestones

Featured News & Press Releases

Feb 27, 2018: Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE (meropenem and vaborbactam) in Patients with cUTI

Jan 30, 2018: Achaogen Announces Upgraded Status for Plazomicin Fill Manufacturer

Oct 26, 2017: Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections

Oct 05, 2017: The Medicines Company to Present New Data from TANGO II Study of VABOMEREâ„¢ (meropenem and vaborbactam) at IDWeek 2017

Oct 05, 2017: Achaogen IDWeek 2017 Presentations Feature Plazomicin’s Unique Potential to Treat MDR Enterobacteriaceae

Oct 04, 2017: Merck Highlights Data on ZERBAXA at ID Week 2017

Sep 27, 2017: Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017

Aug 30, 2017: The Medicines Company Announces FDA Approval of VABOMERE (meropenem and vaborbactam)

Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam

Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis

Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016

Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pyelonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pyelonephritis Pipeline by Achaogen Inc, H1 2018

Pyelonephritis Pipeline by AstraZeneca Plc, H1 2018

Pyelonephritis Pipeline by Entasis Therapeutics Inc, H1 2018

Pyelonephritis Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Pyelonephritis Pipeline by Melinta Therapeutics Inc, H1 2018

Pyelonephritis Pipeline by Merck & Co Inc, H1 2018

Pyelonephritis Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2018

Pyelonephritis Pipeline by Paratek Pharmaceuticals Inc, H1 2018

Pyelonephritis Pipeline by Zavante Therapeutics Inc, H1 2018

Pyelonephritis Dormant Projects, H1 2018

Pyelonephritis Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Pyelonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports